- Home
- STX vs GILD Comparison
STX vs GILD Comparison
Compare STX & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STX | GILD |
|---|---|---|
| Founded | 1978 | 1987 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1B | 187.4B |
| IPO Year | 2002 | 2003 |
Fundamental Metrics
Financial Performance| Metric | STX | GILD |
|---|---|---|
| Price | $702.08 | $154.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 28 |
| Target Price | ★ $1,138.33 | $159.85 |
| AVG Volume (30 Days) | 3.8M | ★ 4.8M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | 0.44% | ★ 2.10% |
| EPS Growth | 105.32 | ★ 1684.21 |
| EPS | ★ 13.90 | N/A |
| Revenue | $7,384,000,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $55.46 | $4.36 |
| Revenue Next Year | $34.80 | $6.88 |
| P/E Ratio | $48.66 | ★ N/A |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $217.67 | $114.02 |
| 52 Week High | $1,145.00 | $160.51 |
Technical Indicators
Market Signals| Indicator | STX | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 56.89 |
| Support Level | $698.17 | $142.91 |
| Resistance Level | $939.07 | $157.29 |
| Average True Range (ATR) | 37.47 | 3.54 |
| MACD | -15.27 | 0.52 |
| Stochastic Oscillator | 21.20 | 64.83 |
Price Performance
Historical ComparisonAbout STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).